Enzyme Replacement Therapy for Rare Disease Granted Breakthrough Designation

Article

The FDA has granted breakthrough therapy designation to Genzyme's olipudase alfa enzyme replacement treatment for nonneurological manifestations of acid sphingomyelinase deficiency.

The FDA has granted breakthrough therapy designation to Genzyme’s investigational olipudase alfa enzyme replacement treatment for nonneurological manifestations of acid sphingomyelinase deficiency (ASMD).

Patients with nonneuronopathic ASMD, also known as Niemann-Pick disease type B, do not produce enough of the enzyme acid sphingomyelinase that breaks down sphingomyelin. When it is not broken down, sphingomyelin accumulates to toxic levels in cells until they can no longer function and eventually die.

Currently, there is no FDA-approved medication to treat nonneuronopathic ASMD.

“There is tremendous unmet need in the ASMD/Niemann-Pick disease type B community, and we are hopeful that olipudase alfa can be developed into a meaningful treatment for patients,” stated Richard Peters, MD, PhD, Genzyme’s global head of rare diseases.

Olipudase alfa is designed to mimic the function of sphingomyelinase and assist in the breakdown of sphingomyelin. The drug’s breakthrough therapy designation was supported by phase 1b study data demonstrating positive results in 5 adult patients with nonneuronopathic ASMD.

Genzyme is starting to enroll subjects in a phase 1/2 pediatric study, and it is also planning enrollment for a phase 2/3 adult study in the second half of 2015.

Related Videos
male pharmacist using digital tablet during inventory in pharmacy | Image Credit: sofiko14 - stock.adobe.com
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.